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Abstract
Neuroendocrine tumors (NETs), defined as epithelial 
tumors with predominant neuroendocrine differenti-
ation, are among the most frequent types of small 
bowel neoplasm. They represent a rare, slow-growing 
neoplasm with some characteristics common to all 
forms and others attributable to the organ of origin. The 
diagnosis of this subgroup of neoplasia is not usually 
straight-forward for several reasons. Being a rare form 
of neoplasm they are frequently not readily considered 
in the differential diagnosis. Also, clinical manifestations 
are nonspecific lending the clinician no clue that points 
directly to this entity. However, the annual incidence of 
NETs has risen in the last years to 40 to 50 cases per 
million probably not due to a real increase in incidence 
but rather due to better diagnostic tools that have 
become progressively available. Being a rare malignancy, 
investigation regarding its pathophysiology and efforts 
toward better understanding and classification of these 
tumors has been limited until recently. Clinical societies 
dedicated to this matter are emerging (NANETS, 
ENETS and UKINETS) and several guidelines were 
published in an effort to standardize the nomenclature, 
grading and staging systems as well as diagnosis and 
management of NETs. Also, some investigation on the 
genetic behavior of small bowel NETs has been recently 
released, shedding some light on the pathophysiology 
of these tumors, and pointing some new directions on 
the possible treating options. In this review we focus on 
the current status of the overall knowledge about small 
bowel NETs, focusing on recent breakthroughs and its 
potential application on clinical practice.
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Core tip: Annual incidence of neuroendocrine tumors 
(NETs) has risen in the last years to 40 to 50 cases 
per million probably due to better diagnostic tools. 
Recurrent loss of chromosomes 11 and 18 and gains 
of chromosomes 4, 5, 19 and 20 have been shown in 
NETs. Several cancer-related pathways were implied in 
NETs associated mutations, including PI3K/Akt/mTOR 
and TGF-β pathways. Genes involved in secretory 
activity were conserved in NETs, however alterations in 
transcription factors associated with neurodevelopmental 
process were reported. Studies suggest that miRNA may 
have a role in ileal NETs development and progression.
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Pathophysiol 2016; 7(1): 117-124  Available from: URL: http://
www.wjgnet.com/2150-5330/full/v7/i1/117.htm  DOI: http://
dx.doi.org/10.4291/wjgp.v7.i1.117
INTRODUCTION
Neuroendocrine tumors (NETs), defined as epithelial 
tumors with predominant neuroendocrine differenti­
ation, are among the most frequent types of small 
bowel neoplasm. They represent a rare, slow­growing 
neoplasm with some characteristics common to all 
forms and others attributable to the organ of origin. The 
diagnosis of this subgroup of neoplasia is not usually 
straight­forward for several reasons. Being a rare form 
of neoplasm they are frequently not readily considered 
in the differential diagnosis. Also, clinical manifestations 
are nonspecific lending the clinician no clue that points 
directly to this entity. However, the annual incidence of 
NETs has risen in the last years to 40 to 50 cases per 
million probably not due to a real increase in incidence 
but rather due to better diagnostic tools that have 
become progressively available.
Being a rare malignancy, investigation regarding 
its pathophysiology and efforts toward better under­
standing and classification of these tumors has been 
limited until recently. Clinical societies dedicated to this 
matter are emerging (NANETS, ENETS and UKINETS) 
and several guidelines were published in an effort to 
standardize the nomenclature, grading and staging 
systems as well as diagnosis and management of NETs. 
Also, some investigation on the genetic behavior of 
small bowel NETs has been recently released, shedding 
some light on the pathophysiology of these tumors, and 
pointing some new directions on the possible treating 
options. 
In this review we focus on the current status of the 
overall knowledge about small bowel NETs, focusing on 
recent breakthroughs and its potential application on 
clinical practice. 
EPIDEMIOLOGY 
Duodenal NETs comprise 1%­3% of all primary duo­
denal tumors and 2.8% of all carcinoid tumors according 
to the PAN­SEER Registry (1973­1999)[1]. According 
to SEER Program, the age­adjusted annual incidence 
of NETs arising from jejunum and ileum is 0.67 per 
100000 and for appendix NETs it is 0.16 per 100000[2]. 
However, data extracted from large autopsies series 
indicates that the incidence of small bowel NETs may 
be up to 0.7%[3]. Also, time­trend analyses have shown 
a rise in the incidence of all these forms of NETs. This 
is probably not due to a real increase in the number of 
cases, but rather due to an increased diagnosis efficacy. 
CLASSIFICATION, GRADING AND 
STAGING
NETs are rare neoplasms and can arise in most organs 
of the body. Some of their features are shared by 
all NETs, while others are attributable to their organ 
of origin[4]. Most of the studies regarding NETs have 
focused on the most frequent locations, such as pancr­
eatic and gastrointestinal, limiting extensive knowledge 
of other less common forms of the disease.
All these features have contributed to the emergence 
of several nomenclatures, grading and classification 
systems. Although most of these systems proved 
themselves useful, the lack of a standard classification 
system has hindered the normalization of NETs classi­
fication and consequently, scientific community wide 
consensus. Since some of these systems are now firmly 
established and no clinical data favors one system 
over the others, it may be unpractical to adopt a single 
system, rejecting the remaining. Thus, while ENETS[5,6] 
favor the use of World Health Organization classification 
system, NANETS[7] propose that some basic data 
elements (proliferative rate, extent of local spread, 
immunohistochemical markers) should be specified and 
documented on pathological reports and that a specified 
system of nomenclature, grading and staging should be 
used. This can assure that the basic data are recorded, 
allowing retrospective comparison of NETs regardless of 
the specific classification system used. 
CLINICAL FEATURES
Regarding clinical features there are several differences 
between duodenal and most distal NETs of jejunum and 
ileum.
Duodenal NETs are usually diagnosed in the sixth 
decade with a slight male predominance[8,9]. There are 
five main forms: Duodenal gastrinoma, the most com­
mon type; duodenal somatostatinoma; non­functioning 
duodenal NETs; duodenal gangliocytic paraganglioma 
and poorly differentiated neuroendocrine duodenal 
carcinomas[4,8]. Some authors also consider periampullary 
NETs as a different category given their different clinical, 
histological and growth behavior[8]. Most duodenal NETs 
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are small, single lesions, usually limited to the mucosa 
and submucosa. Regional lymph node metastases may 
be found in up to 60% of cases, while liver metastasis 
usually occur in less than 10%[8]. Since about 90% of 
duodenal NETs are not associated with clinical syndrome, 
most diagnoses are made accidentally during a routine 
workup or the patient develops symptoms attributable 
to the mass itself[8]. Most frequently reported presenting 
symptoms include pain, jaundice (more frequent in peri­
ampullary NETS), nausea, vomits, diarrhea, obstruction, 
active bleeding or anemia[8,9]. In the minority of duodenal 
NETs that cause a functional syndrome the two main 
presentations are Zollinger­Ellison syndrome (ZES) and 
carcinoid syndrome[6]. 
ZES in duodenal gastrinomas usually presents with 
abdominal pain, diarrhea and reflux esophagitis[10]. Its 
diagnosis requires the demonstration of inappropriate 
hypergastrinemia and there are several conditions 
that can cause hypergastrinemia and complicate the 
diagnosis of a ZES. If the fasting serum gastrin is 1000 
ng/L or greater and gastric pH is less than 2.5 the 
diagnosis is established if the patient is normocalcemic, 
has a normal renal function and doesn’t have pyloric 
obstruction[11]. Duodenal NETs presenting with ZES can 
be sporadic or associated to MEN1 syndrome. While 
sporadic forms usually result from single lesions, MEN1 
display multiple lesions[8,10].
Carcinoid syndrome is usually present in patients 
with liver metastasis[5,12] and is caused by excessive 
secretion of endogenous substances, more frequently 
serotonin. Patients can present with flushing, diarrhea, 
cough, whezzing and carcinoid heart disease[12]. Car­
cinoid heart disease is a right sided cardiac insufficiency, 
and in about 35% of patients that develop this condition 
death arises not due to tumor progression but rather 
to heart failure[12]. Regarding prognosis, patients with 
well­differentiated duodenal NETs have a global 5­years 
survival rate of nearly 85%[13]. The stage of disease 
at diagnosis highly influence prognosis, with 10­years 
survival of 95% for patients with local disease and 10% 
for those with distant metastases[9].
NETs of jejunum and ileum are usually diagnosed 
in the sixth/seventh decade[14] but, in opposition to duo­
denal NETs, have no gender preference. Most of them 
are nonfunctioning tumors but about 20% of patients 
show liver metastases and may present with carcinoid 
syndrome. At diagnosis, lesions are commonly > 2 
cm, with invasion of muscularis propria and metastasis 
to regional lymph nodes[4]. Multiple lesions may be 
found in up to 40% of cases[4]. Clinical manifestations 
include abdominal pain, bowel obstruction, diarrhea, 
weight loss and bleeding[15]. The prognosis of these 
NETs is generally unfavorable when compared with 
other location tumors of comparable size since they 
have a higher tendency to grow and spread before the 
diagnosis is firmed[14,15]. The 5­years survival correlates 
with the stage of disease at diagnosis, being of 65% for 
patients with localized disease and only 36% for those 
with distant metastases[5]. 
PATHOPHYSIOLOGY
Small bowel tumors correspond to 1%­2% of all 
gastrointestinal malignancies, and NETs are only one of 
the subtypes of these rare neoplasms. Being an unusual 
form of oncologic disease, research towards better 
understanding these tumors has been scarce.
Phenotypically these neoplasms are composed by 
neuroendocrine cells which, in the gastrointestinal tract, 
are scattered through the mucosa. These cells get 
their name from their ability to express some proteins 
classically attributable to neural cells, as neuron­specific 
enolase and synaptophysin, and also to their capacity 
to produce hormones, such as somatostatin, substance 
P and VIP. The tumorigenesis of NETs has not yet been 
elucidated, however recent efforts to clarify the genetic 
alterations in these tumors have been made.
Recently, two exome/genome­wide tumor DNA 
sequencing for the small intestine (SI) NET have been 
reported. The first one, from Banck et al[16], matched 
germline DNA of 48 small bowel NETs, with samples 
consisting of well differentiated primary tumors. More 
than 20000 genes were sequenced and the data from 
tumor was compared to normal tissue to identify 
genetic alterations. This study found point mutations, 
termed single nucleotide variants (SNV), at an average 
rate of 0.1 SNV per 106 nucleotides. This classifies small 
bowel NETs as a genomically stable cancer, with low 
mutation rates. SNV were found in 197 genes, most 
of which were known for being cancer genes. Those 
included VHL, BRAF, FGFR2, MEN1, MLF1, SRC, SMAD 
and FANCD2 among others. Banck et al[16] also looked 
for somatic copy number alterations, that consist of 
large deletions or amplifications that can cause the 
inactivation of tumor suppressor genes or the excessive 
expression of oncogenes. This analyses revealed a 
recurrent loss of chromosomes 11 and 18 and gains 
of chromosomes 4, 5, 19 and 20. Furthermore, with 
resource to bioinformatic analysis, several cancer­related 
pathways were implied in these mutations, including 
PI3K/Akt/mTOR and TGF­β pathways. The involvement 
of mTOR pathway support the findings of recent clinical 
trials in which mTOR inhibitors seem active in the 
treatment of some SI NETs[17]. Also, TGF­β pathway 
had previously been implied as a regulator in small 
bowel NETs. A study based on immunohistochemistry 
staining of 104 NETs showed enhanced expression 
of TGF­β in all but 1 tumor[18]. Also, cell lines studies 
suggest that small bowel NET neoplastic cells were 
induced to proliferate by TGF­β1 but the same effect 
was not reproducible in normal small bowel cells[19]. This 
suggests that TGF­β pathway targeting therapies might 
be of use in NETs management, as previously pointed 
out in some studies[20].
Francis et al[21] published a multicenter study of 
whole exome sequencing of 29 small bowel NETs and 
whole genome sequencing of 15 primary small bowel 
NETs, focusing on analysis of small insertion and dele­
tion termed indels. They found recurrent heterozygous 
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and­200) and four were downregulated (miRNA­31, 
­129­5p, ­133a and­215) during tumor progression[28]. 
Although these findings might be promising, there 
is still much to be understood regarding the mech­
anisms behind NETs development. Nevertheless, this 
recent knowledge has allowed to guide the scientific 
community, with the emergence of clinical trials with 
therapies targeting the genetic alterations described so 
far.
BIOMARKERS AND OTHER LABORATORY 
TESTS
Several circulating tumor markers have been evaluated 
for the diagnosis and follow­up of NETs. Currently, 
chromogranin A (CgA) is the most important of these 
markers, and current guidelines recommend measure­
ment of serum CgA at diagnosis[5,6,29]. It consists of a 
polypeptide widely expressed in secretory granules 
of neuroendocrine cells. Plasma CgA is elevated in 
60%­100% of patients with NET, either functioning 
or nonfunctioning, with a sensitivity and specificity for 
detecting NET of 70% to 100%[29]. However, CgA levels 
are influenced by the assay used[30] and are highly 
influenced by several common conditions, and false 
elevation of this marker has been reported in patients 
using proton pump inhibitors, with renal or liver failure 
and even in chronic gastritis[31]. Other proposed markers 
are plasma neuron­specific enolase, urinary 5­HIAA 
(as a marker of carcinoid syndrome) and a variety of 
other secreted amines such as chromogranin B and C, 
substance P, neurotensin, among others[29]. 
In an effort to find better NETs biomarkers, Modlin 
et al[32] recently published a multi­transcript molecular 
signature for PCR blood analysis which may facilitate 
future diagnosis of NETs. They analyzed transcripts of 
3 microarray datasets (NETs peripheral blood, NETs 
tissue and adenocarcinoma) and found 51 significantly 
elevated transcript markers. Based on that, gene­
based classifiers were created and were able to detect 
NETs with high sensitivity (85%­98%), specificity 
(93%­97%), positive predictive value (95%­96%) and 
negative predictive value (87%­98%). The transcript 
marker was similarly effective in recognizing pancreatic 
and gastrointestinal NETs, as well as, metastases. 
Moreover, the gene­based classifier was significantly 
more accurate than CgA and, in patients with low CgA, 
the transcript markers were elevated in 91% of cases[32]. 
This may reflect the future utility of genetic markers as 
diagnostic tools of NETs, however further investigation 
needs to be done to validate this hypothesis.
DIAGNOSTIC IMAGING 
For duodenal NETs diagnosis, upper gastrointestinal 
endoscopy with biopsies (or endoscopic removal of 
the lesion for histopathological assessment whenever 
feasible) is the most sensitive diagnostic test. This 
inactivating indels in the cell cycle inhibitor gene 
CDKN1B in 8% of small bowel NETs. With the release 
of this information, Banck et al[16] reviewed their results 
targeting CDKN1B gene, coming to similar results. This 
finding suggests that cell cycle inhibitory drugs may 
be of interest in the treatment of a subset of patients. 
Curiously, germline mutations in CDKN1B are known 
to cause MEN­4, a cancerous syndrome with known 
association to endocrine NETs, and CDKN1B mutations 
have been implied in other cancers, like colorectal, 
breast and prostate. 
In an effort to understand the expression profiles 
and regulatory networks involved in NETs, Kidd et al[22] 
re­analysed two small intestinal tumor transcriptomes. 
They reported that in small bowel NETs the genes 
involved in secretory activity were conserved; however 
alterations in transcription factors associated with 
neurodevelopmental process were reported, suggesting 
that abnormalities of this process may be relevant in the 
neoplastic evolution. The study group was also able to 
confirm the loss of SDHD expression, a finding usually 
associated with benign tumors. 
Another recent breakthrough in the understanding 
of NETs pathophysiology is the study of microRNAs 
(miRNAs). MicroRNAs consist of small (19­25 nucleo­
tides), non­coding RNAs with the capability to regulate 
the expression of at least one­third of protein­coding 
genes. Their deregulation has been associated with the 
development of cancer, and some subsets of neoplasm 
have been extensively studied in the field of miRNAs 
with results that point to the influence of deregulated 
miRNAs in the staging, prognosis and response to 
therapy[23]. They have the capacity to regulate gene 
expression, to influence neighbor cells and even to be 
packed and transported extracellularly, entering the 
bloodstream, and modulating cells at distant site in an 
hormone­like action[24]. 
This subtype of RNA can be extracted from several 
body fluids, is long­living in vivo and very stable in 
vitro which enables miRNA profiling techniques to 
be extremely sensitive, objective and standardized, 
characteristics that make miRNAs potential biomar­
kers[25]. Also, they can act as potential therapeutic 
targets with preclinical models pointing to the efficacy of 
miRNA based therapies[26]. 
Regarding SI NETs, two recent miRNA expression 
profile studies showed that miRNA deregulation played 
a role in small bowel NETs tumorigenesis. The first one 
associated miRNA­133a downregulation with progression 
from primary to metastatic disease. This suggests that 
this miRNA may have a role in ileal NETs development 
and progression, being a potential marker of diagno­
sis and/or prognosis[27]. Interestingly, miRNA­133a is 
located to chromosome 18, which was shown to be 
recurrently lost in whole genome studies. In the second 
study, the expression of miRNAs in well­differentiated 
small bowel NETs was evaluated, with the goal to 
provide new disease biomarkers. They reported that five 
miRNAs were upregulated (miRNA­96,­182,­183,­196 
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can be coupled with endoscopic ultrasound in order 
to locally stage the disease, by evaluating the depth 
of involvement and the presence of local lymph 
nodes metastases[6,33]. Endoscopic ultrasound may be 
complemented with FNA (fine­needle aspiration) to 
obtain cells in deeper layers such as the submucosa, 
for histological diagnosis. Regarding jejunal and ileal 
NETs, ileocolonoscopy can make the diagnosis in more 
distal lesions but until recently, most of the small bowel 
extent was not accessible to direct mucosal visualization. 
With the evolution of enteroscopic diagnostic tools, 
physicians have now at their disposal new, promising 
diagnostic tools like capsule enteroscopy (CE) and 
balloon­assisted enteroscopy. CE proved itself useful in 
the study of suspected small bowel neoplasms, due to 
its high diagnostic yield and non­invasiveness, obtaining 
high quality endoscopic imaging even in the absence 
of bowel preparation[34]. Also, CE seems better than 
CT and enteroclysis in detecting primary NETs and 
has a similar diagnostic yield as somatostatin receptor 
scintigraphy (SRS) with the advantage that the first one 
can differentiate between intestinal and mesenterial 
localization[35]. In a review of our center epidemiology 
on small bowel tumors diagnosed by CE, 1510 CE 
performed between 2006­2014 were reviewed and 
included those classified as having suspect small bowel 
tumors with ≥ 10 mm dimension. Lesions suspect of SI 
tumor were identified in 19 EC (1.3%), and histological 
confirmation of primary small bowel neoplasm was 
obtained for 6 cases, of which 2 patients were diagnosed 
with NET ­ one duodenal and another ileal ­ (unpublished 
data).
After the diagnosis, thorax x­ray, Helical CT or MRI 
of the abdomen and pelvis coupled with SRS should be 
done to assess disease extent and search for distant 
metastasis[5,6,31]. SRS is an imaging diagnostic test in 
which a somatostatin analog, octreotide, is radiolabeled 
and administered to the patient. Since the majority of 
NETs express one or more subtypes of somatostatin 
receptors, this technique allows detection of local and 
distant disease. In patients with advanced disease, 
especially liver metastases, bone scintigraphy and 
MRI of the spine should also be done to exclude bone 
metastasis[5,6]. 
PET scan using its classic tracer 18F­deoxyglucose is 
not effective in the diagnosis of well differentiated NETs. 
However, using this diagnostic technique with specific 
neuroendocrine tracers has shown good results, with 
better detection of small primary tumors and lymph 
node metastases than CT, MRI and even SRS[36,37]. 
Moreover, for patients with carcinoid syndrome it is 
mandatory to perform an echocardiography to evaluate 
the presence and severity of carcinoid heart disease[5]. 
TREATMENT
Concerning treatment, clinical societies state that 
curative surgery should be aimed for in patients with duo­
denal, jejunal and ileal NETs whenever possible[5,6,29,38]. 
For small (≤ 1 cm) duodenal NETs local endoscopic 
resection is an option but larger duodenal NETs (≥ 2 
cm) or the presence of lymph node metastases should 
be treated surgically[6]. Palliative surgery should be 
offered for those patients with potentially resectable 
hepatic metastases without distant metastases and no 
other medical conditions that can markedly compromise 
life expectancy. In the minority of duodenal NETs that 
display functional hormonal syndromes, specific treat­
ment for hormone excess suppression should be given 
to the patient[6] (Table 1).
Jejunal and ileal NETs have a greater propensity to 
metastasize and are more frequently multiple lesions 
therefore, even in small tumors, surgery should involve 
search for additional tumors by inspection and palp­
ation[29] as well as wide lymphadenectomy[5]. In patients 
with liver metastases curative surgery should still be 
attempted, and intraoperative ultrasonography should 
be performed for detection of all liver metastases[5]. 
Palliative surgery should still be considered to prevent 
complications attributable to the tumor mass in patients 
not suitable for curative resection[5].
In jejunal and ileal NETs with carcinoid syndrome, 
somatostatin analogs effectively reduce symptoms in 
40%­80% of patients. Also, this therapy proved capable 
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Duodenal NETs – Surgical Treatment
≤ 1 cm Local ressection (if possible)
≥ 2 cm OR lymph nodes metastasis Surgical ressection
Potentially resectable hepatic metastases without distant 
metastases and no other significant comorbility
Palliative surgery
Duodenal NETs – farmacological treatment
Functional duodenal NETs Hormone suppression treatment
Well-differentiated NETs Systemic chemotherapy if advanced metastatic disease
Poorly differentiated tumors Combination chemotherapy – variable duration disease remission 
   mTOR, tyrosine kinase and VEGF inhibitors – phase 3 trials with promising results
Metastatic or inoperable disease Peptide receptor radionuclide therapy
   When all other treatment options fail
   If positive octreoscan 
Table 1  Duodenal Neuroendocrine tumors treatment
NETs: Neuroendocrine tumors; VEGF: Vascular endothelial growth factor.
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to induce stabilization of tumor growth in up to 50% of 
cases thus, somastatin analogs are clearly indicated in 
functional jejunal­ileal NETs[5]. Interferon­α can be used 
with the same purpose but its toxicity profile make this 
a second­line treatment option[5,29] (Table 2).
Systemic chemotherapy showed poor results in the 
treatment of small bowel NETs and is not recommended 
for well­differentiated NETs of midgut and hindgut[5] 
and, in well­differentiated duodenal NETs it is reserved 
for those patients with advanced metastatic disease[6]. 
However, in patients with poorly differentiated tumors, 
combination chemotherapy has been shown to in­
duce disease remission with variable duration[39,40]. 
Consequently, for this group of small bowel NETs chemo­
therapy constitutes a treatment option[41,42]. Clinical 
trials using mTOR, tyrosine kinase and VEGF inhibitors 
in the treatment of NETs are currently being developed, 
showing promising results. One trial used patients 
with metastatic or unresectable NETs on stable doses 
of octreoctide and randomized them to association 
treatment with either VEGF inhibitor bevacizumab or 
pegylated (PEG) interferon alfa­2b for 18 wk. Bevacizu­
mab therapy showed greater reduction of blood flow 
and longer progression free survival compared to PEG­
Interferon therapy. However this trial had a limited 
number of patients and a larger Phase 3 confirmatory 
study is underway[43]. A phase 3 study compared the 
association of octreotide long acting­repeatable (LAR) 
with Everolimus, a mTOR inhibitor, versus its association 
with placebo. Median progression­free survival was 16.4 
mo in the everolimus plus octreotide LAR group and 
11.3 mo in the placebo plus octreotide LAR group[17]. 
These findings point to the survival benefit of everolimus 
in the treatment of NETs and although it cannot be 
considered as standard treatment, it can be considered 
for patients without other treatment options[29]. 
For patients with metastatic or inoperable disease 
who have exhausted all other treatment options, 
peptide receptor radionuclide therapy should be con­
sidered if Octreoscan is positive. This treatment uses 
the somatostatin receptor present on the neoplasic 
lesion to deliver radio­labeled peptides directly to it. 
The majority of clinical centers use either 90yttrium or 
177lutetium but a recent study tested the combination 
of both radioisotopes with an improved overall survival 
compared to single radioisotope treatment[44]. Still, 
further studies on this new treatment field need to be 
done. 
CONCLUSION
NETs are an unusual neoplastic disease with several 
unanswered questions regarding its pathophysiology, 
diagnosis and treatment. Recent breakthroughs have 
redirected our approach in therapy clinical trials and may 
bring better diagnostic tools and even new prognostic 
markers. Still much work has to be done in order to fully 
understand this disease.
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